Cargando…

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

BACKGROUND: Two treatments, ranibizumab and dexamethasone implant, for visual impairment due to macular oedema (ME) secondary to retinal vein occlusion (RVO) have recently been studied in clinical trials. There have been no head to head comparisons of the two treatments, and improvement measured as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thom, Howard HZ, Capkun, Gorana, Nixon, Richard M, Ferreira, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289570/ https://www.ncbi.nlm.nih.gov/pubmed/25533265 http://dx.doi.org/10.1186/1471-2288-14-140

Ejemplares similares

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
por: Liang, Xuemei, et al.
Publicado: (2022)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Perifoveal Microcirculation in Macular Oedema with Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Bayat, Alper Halil, et al.
Publicado: (2019)

The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
por: Du, Xing, et al.
Publicado: (2022)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Comparative Evaluation Between Ranibizumab Combined with Laser and Bevacizumab Combined with Laser Versus Laser Alone for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Azad, Shorya Vardhan, et al.
Publicado: (2014)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion
por: Dikel, Nevin Hande, et al.
Publicado: (2019)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review
por: Glanville, Julie, et al.
Publicado: (2014)

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2012)

Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018)

Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension
por: Thom, Howard HZ, et al.
Publicado: (2015)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis
por: Ford, John A, et al.
Publicado: (2014)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Treatments for macular oedema following central retinal vein occlusion: systematic review
por: Ford, John A, et al.
Publicado: (2014)

Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
por: Menke, Marcel N., et al.
Publicado: (2016)

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane, Pearse A, et al.
Publicado: (2011)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
por: Hunter, Alexandra, et al.
Publicado: (2022)

Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
por: Gale, Richard, et al.
Publicado: (2021)

Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion‐related macular oedema: A prospective randomized comparison—Comment
por: Wen, Dejia, et al.
Publicado: (2019)

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
por: Nghiem-Buffet, S, et al.
Publicado: (2017)

Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema
por: Lee, You Hyun, et al.
Publicado: (2020)

Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis
por: Xu, Shanshan, et al.
Publicado: (2022)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Ranibizumab for Macular Edema Secondary to Central and Branch Retinal Vein Occlusion in Patients Younger Than 50 Years of Age
por: Battaglia Parodi, Maurizio, et al.
Publicado: (2020)

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
por: Ford, John A, et al.
Publicado: (2012)

Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion
por: Ozcift, Seda Gurakar, et al.
Publicado: (2023)

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis
por: Regnier, Stephane A, et al.
Publicado: (2015)

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion
por: Donati, Simone, et al.
Publicado: (2018)

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
por: Singer, Michael A, et al.
Publicado: (2013)

Rapid formation of macular pucker following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Oshiro, Ayano, et al.
Publicado: (2021)

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
por: Otawa, Taro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9nsrbim2fp3shdnlnre2k2est